Research Paper Volume 12, Issue 20 pp 20285—20307

LncRNA DGCR5 plays a tumor-suppressive role in glioma via the miR-21/Smad7 and miR-23a/PTEN axes

Figure 2. Expression of lncRNA DGCR5 according to online data and experimental results. (A) LncRNA DGCR5 expression in 27 types of tissues from 95 persons according to online HPA RNA-seq data. (B) LncRNA DGCR5 expression in normal (noncancerous), proneural glioma, neural glioma, mesenchymal glioma, and classical glioma according to TCGA dataset. (C) LncRNA DGCR5 expression in oligodendroglioma, astrocytoma, and glioblastoma according to REMBRANDT dataset. (D) LncRNA DGCR5 expression in oligodendroglioma, astrocytoma, and glioblastoma according to GSE4290. (E) LncRNA DGCR5 expression in different parts of glioma, including leading edge, infiltrating tumor, perinecrotic zone, cellular tumor, pseudopalisading cells around necrosis, hyperplastic blood vessels in cellular tumor, and microvascular proliferation according to Ivy Glioblastoma Atlas Project data. (F) LncRNA DGCR5 expression in normal (noncancerous, n=28) and glioma tissues (stage II n=11, stage III n=9, stage IV n=8) determined by real-time PCR. (G) LncRNA DGCR5 expression in normal human astrocytes, NHA, and glioma cell lines, LN229, U251-MG, SHG44, and T98G was determined by real-time PCR. **P<0.01, ***P<0.005, compared to control group. ###P<0.005, compared to stage II group. $$P<0.01, compared to stage III group.